Metastatic pancreatic cancer

Current Treatment Options in Oncology

Volumn 3, Issue 6, 2002, Pages 449-457

  Kulke, Matthew H ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Clin Oncol; Docetaxel; Gemcitabine; Irinotecan; Pancreatic Cancer

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; GEMCITABINE;

CELIAC PLEXUS; CHOLESTASIS; CLINICAL TRIAL; DIGESTIVE SYSTEM DISEASE; HUMAN; METASTASIS; MULTIMODALITY CANCER THERAPY; NERVE BLOCK; NEURALGIA; PALLIATIVE THERAPY; PANCREAS TUMOR; REVIEW; RISK FACTOR; STENT; STOMACH OBSTRUCTION;

ANTINEOPLASTIC AGENTS; AUTONOMIC NERVE BLOCK; CELIAC PLEXUS; CHOLESTASIS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DIGESTIVE SYSTEM DISEASES; FLUOROURACIL; GASTRIC OUTLET OBSTRUCTION; HUMANS; NEOPLASM METASTASIS; NEURALGIA; PALLIATIVE CARE; PANCREATIC NEOPLASMS; RISK FACTORS; STENTS;

EID: 1342339629     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-002-0065-5     Document Type: Article

References (38)

1. Howe G, Jain M, Burch J, et al.: Cigarette smoking and cancer of the pancreas: evidence from a populationbased case control study in Toronto. Int J Cancer 1991, 47:323–328. DOI: 10.1002/ijc.2910470302
2. Lowenfels A, Maisonneuve P, Cavallini G, et al.: Pancreatitis and the risk of pancreatic cancer. International Pancreatic Cancer Study Group. N Engl J Med 1993, 328:1433–1437. DOI: 10.1056/NEJM199305203282001
3. Everhard J, Wright D: Diabetes mellitus as a risk factor for pancreatic cancer. JAMA 1995, 273:1605–1609. DOI: 10.1001/jama.273.20.1605
4. Michaud DS, Giovannucci E, Willett WC, et al.: Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001, 286:921–929. DOI: 10.1001/jama.286.8.921
5. Crown J, Casper E, Botet J, et al.: Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991, 9:1682–1686.
6. DeCaprio J, Mayer R, Gonin R, et al.: Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol 1991, 9:2128–2133.
7. Cartwright T, Cohn A, Varkey J, et al.: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002, 20:160–164. DOI: 10.1200/JCO.20.1.160
8. Cullinan S, Moertel C, Wieand H, et al.: A phase II trial on the therapy of advanced pancreatic carcinoma: evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 1990, 65:2207–2212. DOI: 10.1002/1097-0142(19900515)65:10<2207::AID-CNCR2820651007>3.0.CO;2-Y
9. Cullinan S, Moertel C, Fleming T, et al.: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil versus fluorouracil and doxorubicin versus fluorouracil, doxorubicin, and mitomycin. JAMA 1985, 253:2061–2067. DOI: 10.1001/jama.253.14.2061
10. Maisey N, Chau I, Norman A, et al.: A randomized trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced pancreatic cancer. Proc ASCO 2001, 20:507A.
11. Casper E, Green M, Kelsen D, et al.: Phase II trial of gemcitabine (2,2’-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994, 12:29–34. DOI: 10.1007/BF00873232
12. Carmichael J, Fink U, Russell R, et al.: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Cancer 1996, 73:101–105.
13. Rothenberg M, Moore M, Cripps M, et al.: A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer. Ann Oncol 1996, 7:347–353.
14. Burris H, Moore M, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403–2413. A pivotal trial establishing gemcitabine as the standard first-line therapy for patients with metastatic cancer.
15. Tempero M, Plunkett W, Haperen VR, et al.: Randomized phase II trial of dose intense gemcitabine by standard infusion versus fixed dose rate in metastatic pancreatic cancer. Proc ASCO 1999, 18:1048A. A trial suggesting that administering gemcitabine using a prolonged infusion may be more effective than standard infusion.
16. Berlin J, Catalano P, Thomas J, et al.: A phase III study of gemcitabine in combination with 5-FU versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J Clin Oncol 2002, 3270-3275.
17. Heinemann V, Wilke H, Mergenthaler HG, et al.: Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000, 11:1399–1403. DOI: 10.1023/A:1026595525977
18. Philip PA, Zalupski MM, Vaitkevicius VK, et al.: Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001, 92:569–577. DOI: 10.1002/1097-0142(20010801)92:3<569::AID-CNCR1356>3.0.CO;2-D
19. Colucci G, Giuliani F, Gebbia V, et al.: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase II study of the Gruppa Oncologia dell’Italia Meridionale. Cancer 2002, 94:902–910. A trial suggesting that combination therapy with gemcitabine and cisplatin may be superior to single-agent gemcitabine. DOI: 10.1002/cncr.10323
20. Sakata Y, Shimada Y, Yoshino M, et al.: [A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer]. Gan To Kagaku Ryoho 1994, 21:1039–1046.
21. Wagener DJ, Verdonk HE, Dirix LY, et al.: Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995, 6:129–132.
22. Rocha-Lima C, Savarese D, Bruckner H, et al.: Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002, 20:1182–1191. A trial demonstrating encouraging results with the combination of gemcitabine and irinotecan. DOI: 10.1200/JCO.20.5.1182
23. Reni M, Passoni P, Panucci M, et al.: Definitive results of a phase II trial of cisplatin, epirubicin, continuous infusion fluorouracil and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol 2001, 19:2679–2686. A trial demonstrating high response rates with combination therapy in patients with pancreatic cancer.
24. Bramhall S, Rosemurgy A, Brown P, et al.: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001, 19:3447–3455.
25. Louvet C, Andre T, Lledo G, et al.: Gemcitabine-oxaliplatin (GEMOX) combination in advanced pancreatic carcinoma: a Gercor multicenter phase II study. Proc ASCO 2001, 20:506A.
26. Smith A, Dowsett J, Russell R, et al.: Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. Lancet 1994, 344:1655–1660. DOI: 10.1016/S0140-6736(94)90455-3
27. Soetikno R, Lichtenstein D, Vandervoort J, et al.: Palliation of malignant gastric outlet obstruction using an endoscopically placed Wallstent. Gastrointest Endosc 1998, 47:267–270. DOI: 10.1016/S0016-5107(98)70325-6
28. Brodowicz T, Wolfram RM, Kostler WJ, et al.: Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer. Anticancer Drugs 2000, 11:623–628. DOI: 10.1097/00001813-200009000-00004
29. Okada S, Sakata Y, Matsuno S, et al.: Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan. Br J Cancer 1999, 80:438–443. DOI: 10.1038/sj.bjc.6690375
30. Androulakis N, Kourousis C, Dimopoulos MA, et al.: Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J Clin Oncol 1999, 17:1779–1785.
31. Rougier P, Adenis A, Ducreux M, et al.: A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 2000, 36:1016–1025. DOI: 10.1016/S0959-8049(00)00072-1
32. Abbruzzese J, Evans D, Gravel D, et al.: Docetaxel, a potentially active agent for patients with pancreatic adenocarcinomas. Proc ASCO 1995, 14.
33. Stathopoulos GP, Mavroudis D, Tsavaris N, et al.: Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2001, 12:101–103. DOI: 10.1023/A:1008310106171
34. Sherman WH, Fine RL: Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas. Oncology 2001, 60:316–321. DOI: 10.1159/000058527
35. Ryan DP, Kulke MH, Fuchs CS, et al.: A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 2002, 94:97–103. DOI: 10.1002/cncr.10202
36. Jacobs A, Otero H, Picozzi V Jr, et al.: A phase I/II study of gemcitabine and docetaxel in patients with unresectable pancreatic cancer. Proc ASCO 2001, 20:1029A.
37. Safran H, Ramanathan R, Schwartz J, et al.: Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Proc ASCO 2001, 20:517A.
38. Abbruzzese J, Rosenberg A, Xiong Q, et al.: Phase II study of anti-epidermal growth factor receptor antibody cetuximab in combination with gemcitabine in patients with advanced pancreatic cancer. Proc ASCO 2001, 20:518A.